Fulgent Genetics, Inc. (FLGT): Price and Financial Metrics

Fulgent Genetics, Inc. (FLGT): $36.09

0.16 (+0.45%)

POWR Rating

Component Grades














  • FLGT scores best on the Quality dimension, with a Quality rank ahead of 94.16% of US stocks.
  • The strongest trend for FLGT is in Growth, which has been heading down over the past 177 days.
  • FLGT ranks lowest in Growth; there it ranks in the 0th percentile.

FLGT Stock Summary

  • With a price/earnings ratio of 3.89, FULGENT GENETICS INC P/E ratio is greater than that of about just 7.18% of stocks in our set with positive earnings.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.11 for FULGENT GENETICS INC; that's greater than it is for just 9.57% of US stocks.
  • As for revenue growth, note that FLGT's revenue has grown -22.49% over the past 12 months; that beats the revenue growth of merely 8.22% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to FULGENT GENETICS INC are LUNG, AEYE, QUOT, ADN, and WKME.
  • Visit FLGT's SEC page to see the company's official filings. To visit the company's web site, go to www.fulgentgenetics.com.

FLGT Valuation Summary

  • In comparison to the median Healthcare stock, FLGT's price/earnings ratio is 83.33% lower, now standing at 3.9.
  • Over the past 75 months, FLGT's price/sales ratio has gone down 15.

Below are key valuation metrics over time for FLGT.

Stock Date P/S P/B P/E EV/EBIT
FLGT 2022-12-02 1.3 0.8 3.9 2.5
FLGT 2022-12-01 1.3 0.8 3.9 2.5
FLGT 2022-11-30 1.3 0.8 3.9 2.5
FLGT 2022-11-29 1.3 0.8 3.8 2.4
FLGT 2022-11-28 1.3 0.8 3.9 2.5
FLGT 2022-11-25 1.4 0.9 4.0 2.5

FLGT Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at 91.42%.
  • Its 5 year net income to common stockholders growth rate is now at 91.42%.
  • The 5 year revenue growth rate now stands at 91.02%.
FLGT's revenue has moved down $106,804,000 over the prior 15 months.

The table below shows FLGT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 802.935 297.399 271.574
2022-06-30 925.148 428.824 392.377
2022-03-31 953.423 493.809 460.652
2021-12-31 992.584 538.577 507.364
2021-09-30 1,035.891 595.747 569.332
2021-06-30 909.739 452.961 493.448

FLGT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FLGT has a Quality Grade of C, ranking ahead of 74.39% of graded US stocks.
  • FLGT's asset turnover comes in at 1.214 -- ranking 12th of 81 Healthcare stocks.
  • MGLN, UHS, and ADUS are the stocks whose asset turnover ratios are most correlated with FLGT.

The table below shows FLGT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.214 0.793 1.237
2021-03-31 1.514 0.793 1.595
2020-12-31 1.489 0.787 1.426
2020-09-30 1.037 0.692 0.646
2020-06-30 0.522 0.559 0.028
2020-03-31 0.472 0.565 -0.007

FLGT Price Target

For more insight on analysts targets of FLGT, see our FLGT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $103.00 Average Broker Recommendation 1.5 (Moderate Buy)

FLGT Stock Price Chart Interactive Chart >

Price chart for FLGT

FLGT Price/Volume Stats

Current price $36.09 52-week high $109.55
Prev. close $35.93 52-week low $31.07
Day low $35.51 Volume 222,500
Day high $36.41 Avg. volume 363,348
50-day MA $37.32 Dividend yield N/A
200-day MA $49.99 Market Cap 1.06B

Fulgent Genetics, Inc. (FLGT) Company Bio

Fulgent Genetics, Inc., a technology company, focuses on providing genetic testing services to physicians with clinically actionable diagnostic information. It intends to provide tests to hospitals and medical institutions. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is based in Temple City, California.

FLGT Latest News Stream

Event/Time News Detail
Loading, please wait...

FLGT Latest Social Stream

Loading social stream, please wait...

View Full FLGT Social Stream

Latest FLGT News From Around the Web

Below are the latest news stories about FULGENT GENETICS INC that investors may wish to consider to help them evaluate FLGT as an investment opportunity.

The 7 Best Mid-Cap Stocks to Buy Right Now

Those wanting growth potential without the stuffiness of the blue chips should consider the best mid-cap stocks to buy.

Josh Enomoto on InvestorPlace | December 1, 2022

1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings

Fulgent Genetics (NASDAQ: FLGT) has been a fascinating company to watch over the past few years. While that's an impressive market beat, there was a point in early 2021 when Fulgent's stock was up over 1,300%. This wild stock movement was spurred on by incredible revenue growth due to Fulgent's ability to pivot to providing COVID-19 tests early in 2020.

Yahoo | November 24, 2022

Fulgent Genetics to Participate in Piper Sandler’s 34th Annual Healthcare Conference

TEMPLE CITY, Calif., November 17, 2022--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based genetic testing and therapeutics company focused on transforming patient care in oncology, infectious and rare diseases, reproductive health, and pathology, today announced that members of its management team are scheduled to participate in the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022.

Yahoo | November 17, 2022

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

The latest analyst coverage could presage a bad day for Fulgent Genetics, Inc. ( NASDAQ:FLGT ), with the analysts...

Yahoo | November 16, 2022

Fulgent Genetics, Inc. 2022 Q3 - Results - Earnings Call Presentation

The following slide deck was published by Fulgent Genetics, Inc. in conjunction with their 2022 Q3 earnings call.


SA Transcripts on Seeking Alpha | November 9, 2022

Read More 'FLGT' Stories Here

FLGT Price Returns

1-mo 1.60%
3-mo -16.86%
6-mo -27.70%
1-year -57.62%
3-year 205.07%
5-year 905.29%
YTD -64.12%
2021 93.07%
2020 303.88%
2019 306.94%
2018 -27.63%
2017 -62.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8258 seconds.